All-in-one microfluidic design to integrate vascularized tumor spheroid into high-throughput platform
- Authors
- Kim, Youngtaek; Ko, Jihoon; Shin, Nari; Park, Seonghyuk; Lee, Seung-Ryeol; Kim, Suryong; Song, Jiyoung; Lee, Seokjun; Kang, Kyung-Sun; Lee, Jeeyun; Jeon, Noo Li
- Issue Date
- Dec-2022
- Publisher
- WILEY
- Keywords
- all-in-one; high-throughput experimentation; microfluidics; organ-on-a-chip; patient-derived cancer cells (PDCs); tumor microenvironment (TME); vascularized tumor spheroid
- Citation
- BIOTECHNOLOGY AND BIOENGINEERING, v.119, no.12, pp.3678 - 3693
- Journal Title
- BIOTECHNOLOGY AND BIOENGINEERING
- Volume
- 119
- Number
- 12
- Start Page
- 3678
- End Page
- 3693
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87279
- DOI
- 10.1002/bit.28221
- ISSN
- 0006-3592
- Abstract
- The development of a scalable and highly reproducible in vitro tumor microenvironment (TME) platform still sheds light on new insights into cancer metastasis mechanisms and anticancer therapeutic strategies. Here, we present an all-in-one injection molded plastic array three-dimensional culture platform (All-in-One-IMPACT) that integrates vascularized tumor spheroids for highly reproducible, high-throughput experimentation. This device allows the formation of self-assembled cell spheroids on a chip by applying the hanging drop method to the cell culture channel. Then, when the hydrogel containing endothelial cells and fibroblasts is injected, the spheroid inside the droplet can be patterned together in three dimensions along the culture channel. In just two steps above, we can build a vascularized TME within a defined area. This process does not require specialized user skill and minimizes error-inducing steps, enabling both reproducibility and high throughput of the experiment. We have successfully demonstrated the process, from spheroid formation to tumor vascularization, using patient-derived cancer cells (PDCs) as well as various cancer cell lines. Furthermore, we performed combination therapies with Taxol (paclitaxel) and Avastin (bevacizumab), which are used in standard care for metastatic cancer. The All-in-One IMPACT is a powerful tool for establishing various anticancer treatment strategies through the development of a complex TME for use in high-throughput experiments.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 바이오나노대학 > 바이오나노학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/87279)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.